Poseida Therapeutics (NASDAQ:PSTX) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a $20.00 price target on the stock.

Poseida Therapeutics Trading Up 9.4 %

NASDAQ PSTX opened at $3.95 on Thursday. The company has a fifty day simple moving average of $2.98 and a two-hundred day simple moving average of $3.05. Poseida Therapeutics has a 12-month low of $1.60 and a 12-month high of $4.27. The company has a quick ratio of 2.56, a current ratio of 2.56 and a debt-to-equity ratio of 0.69.

Poseida Therapeutics (NASDAQ:PSTX) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.18. The business had revenue of $28.14 million during the quarter, compared to analysts’ expectations of $11.25 million. Poseida Therapeutics had a negative net margin of 131.95% and a negative return on equity of 97.36%. On average, equities research analysts expect that Poseida Therapeutics will post -1.61 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Bayesian Capital Management LP purchased a new position in shares of Poseida Therapeutics during the first quarter worth $33,000. Dynamic Technology Lab Private Ltd acquired a new stake in Poseida Therapeutics during the fourth quarter valued at $36,000. Tower Research Capital LLC TRC grew its position in Poseida Therapeutics by 110.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company’s stock valued at $36,000 after buying an additional 5,606 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in shares of Poseida Therapeutics in the fourth quarter valued at about $76,000. Finally, Lazard Asset Management LLC grew its position in shares of Poseida Therapeutics by 280.3% in the first quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock valued at $91,000 after purchasing an additional 21,138 shares during the period. Hedge funds and other institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.